2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
22
Lung Neoplasms
9
Lymphoma, Large-Cell, Anaplastic
4
Carcinoma
4
Carcinoma, Squamous Cell
2
Carcinoma, Large Cell
2
Brain Neoplasms
2
Adenocarcinoma
2
ALK-positive Advanced NSCLC
2
Sexual Dysfunction, Physiological
1
Neuroma, Acoustic
1
Neurofibromatosis 2
1
Neoplasms
1
Neoplasm Metastasis
1
NSCLC
1
Meningioma
1
Granuloma, Plasma Cell
1
Gastrointestinal Neoplasms
1
Eunuchism
1
Erectile Dysfunction
1
Ependymoma
1
Disease Progression
1
Carcinoma, Pancreatic Ductal
1
Breast Neoplasms
1
ALK-positive NSCLC
1
ALK+ Advanced NSCLC
1
Interventions
Temozolomide
26
Magnetic Resonance Spectroscopy
19
Etoposide
14
Cyclophosphamide
13
Radiotherapy
11
Filgrastim
10
Bevacizumab
10
Carboplatin
9
Biopsy
8
Cisplatin
7
X-Rays
6
Thiotepa
6
Specimen Handling
6
Phantoms, Imaging
6
Carmustine
6
Radiation
5
Nuclear Medicine Department, Hospital
5
Nivolumab
5
Irinotecan
5
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole
5
sargramostim
4
Vincristine
4
Peripheral Blood Stem Cell Transplantation
4
Methotrexate
4
Erlotinib Hydrochloride
4
Azacitidine
4
olaparib
3
etoposide phosphate
3
Surveys and Questionnaires
3
Surgical Procedures, Operative
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ependymoma
×
brigatinib
×
Clear all
NCT04374305
2026-05-06
INTUITT-NF2
Massachusetts General Hospital
Phase 2
Recruiting
109 enrolled